This Month in Gastroenterology

(A) Proportions of total diarrhea morbidity accounted for by acute (<7 days), prolonged (7–13 days), and persistent (≥14 days) episodes and by days of illness. (B) Proportional hazard curves of time to first persistent diarrhea (≥14 days) episode in children with or without a prolonged episode of diarrhea (7–13 days) in the first year of life.

Cumulative incidences of all-cause mortality or rehospitalization for acute coronary syndromes for the clopidogrel plus H2RA cohort, the clopidogrel plus PPI cohort, the clopidogrel alone cohort, the H2RA alone cohort, the and PPI alone cohort.

Phospho-sulindac (P-S) is a safe and effective antitumor agent against colon cancer in vivo. (A) Acute gastrointestinal toxicity of sulindac and P-S. Rats were treated with P-S, sulindac, indomethacin or vehicle and at day 5, the number and sizes of small intestinal ulcerations were counted and scored. (B) Survival curve for mice treated daily for 3 weeks with equimolar doses of P-S or sulindac. (C) Effect of P-S and sulindac on colon cancer xenografts in nude mice. Left panel: Tumor volume growth over time for each treatment. Center panel: Photographs of mouse xenografts. Right panel: Mass of dissected xenographs. All values are means + SEM. *P < .05 versus vehicle-treated mice; ^#P < .05 versus sulindac-treated mice.

FGF-7 activates a cytoprotective response in the liver. FGFR1/2 knockout (ko) mice and control (ctrl) littermates were injected intraperitoneally with saline or 5 μg FGF7. Mice were humanely killed 10 or 30 minutes after injection, and RNAs from the liver were analyzed by qRT-PCR for expression of Dbp and Tef (top panels) or Cyp2a5 and Cyp2c38 (bottom panels).